Publications by authors named "Surapon Nitikraipot"

3 Publications

  • Page 1 of 1

Analysis of Characteristics and Clinical Outcomes for Crisis Management during the Four Waves of the COVID-19 Pandemic.

Int J Environ Res Public Health 2021 11 30;18(23). Epub 2021 Nov 30.

Research and Innovation Division, Thammasat University, Pathum Thani 12121, Thailand.

This study aims to analyze the patient characteristics and factors related to clinical outcomes in the crisis management of the COVID-19 pandemic in a field hospital. We conducted retrospective analysis of patient clinical data from March 2020 to August 2021 at the first university-based field hospital in Thailand. Multivariable logistic regression models were used to evaluate the factors associated with the field hospital discharge destination. Of a total of 3685 COVID-19 patients, 53.6% were women, with the median age of 30 years. General workers accounted for 97.5% of patients, while 2.5% were healthcare workers. Most of the patients were exposed to coronavirus from the community (84.6%). At the study end point, no patients had died, 97.7% had been discharged home, and 2.3% had been transferred to designated high-level hospitals due to their condition worsening. In multivariable logistic regression analysis, older patients with one or more underlying diseases who showed symptoms of COVID-19 and whose chest X-rays showed signs of pneumonia were in a worse condition than other patients. In conclusion, the university-based field hospital has the potential to fill acute gaps and prevent public agencies from being overwhelmed during crisis events.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
November 2021

Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital.

J Infect Public Health 2021 09 31;14(9):1206-1211. Epub 2021 Jul 31.

Chairman of the Executive Committee, Thammasat University Hospital, Pathumthani, Thailand.

Background: Coronavirus disease 2019 (COVID-19) has affected over 145 million infected people and 3 million deaths worldwide. There has been limited data to recommend either for or against use of antiviral regimens in mild COVID-19 patients. This study aimed to compare clinical outcomes between mild COVID-19 patients receiving antiviral drugs and those without.

Method: Thai patients diagnosed with COVID-19 at field hospital affiliated to Thammasat University Hospital, Thailand were evaluated between January 1, 2020 and April 13, 2021. Patients' data, clinical presentation, past medical history, laboratory results, and treatment outcomes were extensively reviewed.

Results: Five hundred patients with positive tests were included in the study. The mean age was 35.9 years; 46% males. There were 225 (45%), 207 (41.4%), 44 (8.8%), 18 (3.6%), 6 (1.2%) patients with asymptomatic, mild, moderate, severe, and critical COVID-19, respectively. Of 207 mild COVID-19 patients, 9 (4.3%) received lopinavir/ritonavir or darunavir/ritonavir, 17 (8.2%) received favipiravir, while 175 (84.5%) had only supportive care. Mild COVID-19 patients receiving antiviral treatment had longer median length of hospital stay [13 days (IQR 11-14) vs. 10 days (IQR 8-12), p < 0.001] than patients having only supportive treatment. Antiviral drug use was significantly associated with longer hospital stay (>10 days) in mild COVID-19 patients (OR 5.52; 95%CI 2.12-14.40, p < 0.001). Adverse drug reactions such as diarrhea, abdominal pain, and hepatitis were also demonstrated in our COVID-19 patients with antiviral treatments. Majority of patients (97.6%) recovered without any complications and were discharged home. Two deaths were caused by acute respiratory distress syndrome from severe COVID-19 pneumonia.

Conclusion: Antiviral treatment could not provide superior clinical outcomes to supportive care in mild COVID-19 patients. Mild COVID-19 patients receiving antiviral medication had longer length of hospital stay than those without. Standard supportive care and regular monitoring of disease progression might be keys for successful management of mild COVID-19.
View Article and Find Full Text PDF

Download full-text PDF

Source Listing
September 2021